

* Returns not adjusted for payouts
Company Profile
Citi Pharma Limited incorporated as a private limited company in Pakistan under the repealed Companies Ordinance, 1984 on October 08, 2012. The principal activity of the company is manufacturing and sale of pharmaceuticals, medical chemicals and botanical products.
Rizwan Sheikh | CEO |
Nadeem Amjad | Chairperson |
Muhammad Riaz | Company Secretary |
F.D Registrar Services (Pvt.) Ltd.
Aslam Malik & Co. Chartered Accountants
June
Equity Profile
Announcements
Date | Title | Document |
---|---|---|
Sep 28, 2023 | Financial Results for the year ended 30-06-2023 | View PDF |
Apr 28, 2023 | Transmission of Quarterly Report for the Period ended March 31, 2023 | View PDF |
Apr 28, 2023 | Financial Results for the 3rd Quarter ended March 31, 2023 | View PDF |
Apr 28, 2023 | Half Yearly Progress Report for the Period ended December 31, 2022 | View PDF |
Apr 28, 2023 | Annual Progress Report for the Period ended June 30, 2022 | View PDF |
Apr 28, 2023 | Half Yearly Progress Report for the period ended December 31, 2021 | View PDF |
Mar 1, 2023 | Transmission of Half Yearly Report for the period ended December 31, 2022 | View PDF |
Feb 28, 2023 | Financial Results for the 2nd Quarter Ended December 31, 2022 | View PDF |
Oct 31, 2022 | Transmission of Quarterly Report for the Period Ended September 30, 2022 | View PDF |
Oct 28, 2022 | Financial Results for the Quarter ended September 30, 2022 | View PDF |
Oct 7, 2022 | Transmission of Annual Report for the year ended June 30, 2022 | View PDF |
Date | Title | Document |
---|---|---|
Sep 21, 2023 | Board Meeting | View |
May 29, 2023 | Results of Board Meeting 26-05-2023 | View PDF |
May 26, 2023 | Emergent Board Meeting in Progress | View |
May 25, 2023 | Board Meeting | View |
Apr 20, 2023 | Board Meeting | View |
Feb 27, 2023 | Board Meeting in Progress | View |
Feb 20, 2023 | Board Meeting | View |
Nov 11, 2022 | Resolutions adopted in Annual General Meeting | View PDF |
Oct 21, 2022 | Board Meeting | View |
Oct 7, 2022 | Notice of Annual General Meeting | View PDF |
Sep 16, 2022 | Board Meeting | View |
Date | Title | Document |
---|---|---|
Sep 21, 2023 | Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations | View |
Sep 21, 2023 | Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations | View |
Jan 2, 2023 | Corporate Briefing Session | View PDF |
Oct 28, 2022 | Appointment of Chairman & CEO | View PDF |
Oct 28, 2022 | Change of Management | View PDF |
Oct 21, 2022 | Notice of Election of Directors under section 159(4) of Companies Act, 2017 | View PDF |
Feb 22, 2022 | Material Information | View PDF |
Feb 18, 2022 | Material Information | View PDF |
Dec 31, 2021 | Material Information | View |
Nov 25, 2021 | Credit of Final Cash Dividend | View |
Nov 22, 2021 | Material Information | View |
Nov 18, 2021 | Credit of Bonus Share Certificates | View PDF |
Financials
All numbers in thousands (000's) except EPS
2023 | 2022 | 2021 | 2020 | |
---|---|---|---|---|
Sales | 12,396,983 | 9,779,880 | 5,795,404 | 3,527,625 |
Profit after Taxation | 657,984 | 635,884 | 351,768 | 143,416 |
EPS | 2.88 | 2.88 | 3.64 | 31.87 |
Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | |
---|---|---|---|---|
Sales | 2,688,728 | 3,052,798 | 3,118,074 | 2,748,139 |
Profit after Taxation | 92,766 | 294,828 | 145,809 | 207,449 |
EPS | 0.41 | 1.29 | 0.64 | 0.92 |

Ratios
2023 | 2022 | 2021 | 2020 | |
---|---|---|---|---|
Gross Profit Margin (%) | 12.16 | 13.83 | 13.47 | 12.39 |
Net Profit Margin (%) | 5.31 | 6.50 | 6.07 | 4.07 |
EPS Growth (%) | (20.88) | (88.58) | 415.70 | |
PEG | (0.54) | (0.11) |
Payouts
Date | Financial Results | Details | Book Closure |
---|---|---|---|
September 28, 2023 4:07 PM | 30/06/2023(YR) | 25%(F) (D) | 20/10/2023 - 27/10/2023 |
September 30, 2021 9:32 PM | 30/06/2021(YR) | 15% (D) - 10% (B) | 21/10/2021 - 28/10/2021 |